Pandemic mutations prompt antibody collaborations
A trial testing a combination of Lilly and Vir antibodies is the latest attempt by developers to stay ahead of the virus that causes Covid-19.
Vir becomes a biotech bubble poster child
The company surges 74% though its hints of clinical activity concern just six hep B patients and could include those on placebo.
Toxicity concerns now hit the Covid antibody approach
An NIAID-sponsored study of a Lilly antibody has been paused for possible toxicity, prompting speculation over the cause of the problem.
Two Covid-19 antibodies look better than one for Lilly
Lilly’s doublet might be superior to Regeneron’s cocktail, but timing and manufacturing issues could now come into play.
Lilly leads the Covid antibody charge
LY-CoV555 shows promising signs for the antibody approach, with Regeneron not far behind.
EASL 2020 – Assembly finds a partner as hepatitis B inches forward
As fresh data confirm the promise of RNAi technology in hepatitis B, Assembly brings on Arbutus for its combo strategy.
Biopharma shares shake off the pandemic
Global drug stocks enthusiastically joined the recovery on the financial markets in the second quarter, more than offsetting earlier declines.
Legend joins the billion-dollar club
With a $3.2bn valuation ahead of its Nasdaq float – and a market cap that is now 50% higher – Legend Biotech enters the IPO record books.
Here come the anti-Covid antibodies
Behind Lilly’s LY-CoV555 come numerous biopharma antibody projects bidding to enter clinical development.
